Optimum Therapeutics, LLC - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Optimum Therapeutics, LLC - Product Pipeline Review - 2014', provides an overview of the Optimum Therapeutics, LLC's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Optimum Therapeutics, LLC's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Optimum Therapeutics, LLC including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Optimum Therapeutics, LLC's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Optimum Therapeutics, LLC's pipeline products Reasons to buy - Evaluate Optimum Therapeutics, LLC's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Optimum Therapeutics, LLC in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Optimum Therapeutics, LLC's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Optimum Therapeutics, LLC and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Optimum Therapeutics, LLC - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Optimum Therapeutics, LLC and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Optimum Therapeutics, LLC Snapshot 4 Optimum Therapeutics, LLC Overview 4 Key Information 4 Key Facts 4 Optimum Therapeutics, LLC - Research and Development Overview 5 Key Therapeutic Areas 5 Optimum Therapeutics, LLC - Pipeline Review 6 Pipeline Products by Stage of Development 6 Pipeline Products - Monotherapy 7 Optimum Therapeutics, LLC - Pipeline Products Glance 8 Optimum Therapeutics, LLC - Clinical Stage Pipeline Products 8 Phase II Products/Combination Treatment Modalities 8 Optimum Therapeutics, LLC - Early Stage Pipeline Products 9 Preclinical Products/Combination Treatment Modalities 9 Discovery Products/Combination Treatment Modalities 10 Optimum Therapeutics, LLC - Drug Profiles 11 suramin hexasodium 11 Product Description 11 Mechanism of Action 11 R&D Progress 11 Paclitaxel CR 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 RNAi Oligonucleotides to Inhibit Survivin for Pancreatic Cancer 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 Optimum Therapeutics, LLC - Pipeline Analysis 16 Optimum Therapeutics, LLC - Pipeline Products by Target 16 Optimum Therapeutics, LLC - Pipeline Products by Route of Administration 17 Optimum Therapeutics, LLC - Pipeline Products by Molecule Type 18 Optimum Therapeutics, LLC - Pipeline Products by Mechanism of Action 19 Optimum Therapeutics, LLC - Locations And Subsidiaries 20 Head Office 20 Appendix 21 Methodology 21 Coverage 21 Secondary Research 21 Primary Research 21 Expert Panel Validation 21 Contact Us 22 Disclaimer 22
List of Tables Optimum Therapeutics, LLC, Key Information 4 Optimum Therapeutics, LLC, Key Facts 4 Optimum Therapeutics, LLC - Pipeline by Indication, 2014 5 Optimum Therapeutics, LLC - Pipeline by Stage of Development, 2014 6 Optimum Therapeutics, LLC - Monotherapy Products in Pipeline, 2014 7 Optimum Therapeutics, LLC - Phase II, 2014 8 Optimum Therapeutics, LLC - Preclinical, 2014 9 Optimum Therapeutics, LLC - Discovery, 2014 10 Optimum Therapeutics, LLC - Pipeline by Target, 2014 16 Optimum Therapeutics, LLC - Pipeline by Route of Administration, 2014 17 Optimum Therapeutics, LLC - Pipeline by Molecule Type, 2014 18 Optimum Therapeutics, LLC - Pipeline Products by Mechanism of Action, 2014 19
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.